SCHEMBL4858561

SCHEMBL4858561

CN1CCNC[C]1c1ncc[nH]1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 2/20 0.36
BRD4 O60885 1/20 0.35
MTOR P42345 1/20 0.34
ADK P55263 1/20 0.34
KCNH2 Q12809 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
ALOX15 P16050 1/20 0.33
ALDH1A1 P00352 4/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
SMPD3 Q9NY59 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
KDM4E B2RXH2 2/20 0.30
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2D6 P10635 1/20 0.30
CYP19A1 P11511 1/20 0.30
CYP2C9 P11712 1/20 0.30
CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11019166 0.69 HTR7 (0.48) NISCHALOX15ALDH1A1SMN1; SMN2KDM4E
SCHEMBL21852313 0.67 NISCH (0.39) NISCHBRD4MTORADKKCNH2
SCHEMBL3976296 0.65 HTR1A (0.41) MEN1KMT2A
SCHEMBL81650 0.63 NISCH (0.59) NISCHBRD4MTORADKALOX15
Methylpiperazine SCHEMBL28192485 0.63 ALDH1A1 (0.59) ALOX15ALDH1A1SMN1; SMN2KDM4E
SCHEMBL16427491 0.63 NISCH (0.37) NISCHMTORADKALDH1A1SMN1; SMN2
SCHEMBL30417024 0.62 ADRB2 (0.51) NISCHMTORADKKCNH2HRH3
Hydrochloric Acid SCHEMBL1536214 0.61 NISCH (0.56) NISCHBRD4MTORADKALDH1A1
SCHEMBL28425230 0.61 NISCH (0.56) NISCHBRD4MTORADKALOX15
SCHEMBL7932131 0.61 NISCH (0.46) NISCHBRD4MTORADKKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040024040-A1 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2004-02-05 US claimed
WO-2003011287-A1 PYRAZOLON DERIVATIVES AS INHIBITORS OF GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2003-02-13 WO claimed
US-7452873-B2 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-18 US disclosed
US-20050222237-A1 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2005-10-06 US disclosed
US-6916798-B2 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-07-12 US disclosed
US-20040024040-A1 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2004-02-05 US disclosed
WO-2003011287-A1 PYRAZOLON DERIVATIVES AS INHIBITORS OF GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2003-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024040-A1 Inhibitors of GSK-3 and uses thereof GSK3B, AURKC, GSK3A NISCH 4657/4885BRD4 1432/4885MTOR 273/4885
US-20050222237-A1 Inhibitors of GSK-3 and uses thereof GSK3B, AURKC, GSK3A NISCH 4657/4885BRD4 1432/4885MTOR 273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.